From the therapeutic perspective, cancer cells with BRCA1/2 mutations are very sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors because PARP inhibitors cause an increase in DNA single-strand breaks, which are then converted to irreparable toxic DNA DSBs in those cells during replication [3]. The gene discussed is BRCA1; the disease is cancer.